An overview of pazopanib in metastatic renal cell carcinoma (mRCC) in Ministry of Health (MOH), Malaysia: A multicentre experience

被引：0
|
作者：
Malwinder, S. [1 ]
Nurazzahra, K. [2 ]
Sandya, S. [2 ]
Chen, M. [1 ]
机构：
[1] Hosp Sultan Ismail, Dept Radiotherapy & Oncol, Johor Baharu, Malaysia
[2] Hosp Kuala Lumpur, Dept Radiotherapy & Oncol, Kuala Lumpur, Malaysia
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
277P
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Experience with pazopanib in the treatment of metastatic renal cell carcinoma: a monocentric experience
    Gernone, Angela
    TUMORI JOURNAL, 2014, 100 (04): : E165 - E168
  • [2] Complications of pazopanib in metastatic renal cell carcinoma (mRCC) in a single tertiary centre: a case series
    Alagappan, K.
    Nasuha, N. A.
    BJU INTERNATIONAL, 2019, 123 : 8 - 8
  • [3] An indirect comparison analysis of pazopanib versus other agents in metastatic renal cell carcinoma (mRCC)
    McCann, L.
    Amit, O.
    Pandite, L.
    Amado, R. G.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [4] Pazopanib for the Treatment of Metastatic Renal Cell Carcinoma
    Pick, Amy M.
    Nystrom, Kelly K.
    CLINICAL THERAPEUTICS, 2012, 34 (03) : 511 - 520
  • [5] Real world outcomes of patients with metastatic renal cell carcinoma (mRCC) using first-line sunitinib or pazopanib: the Canadian experience
    Lalani, A-K.
    Li, H.
    Heng, D.
    Wood, L.
    Kalirai, A.
    Bjarnason, G.
    Sim, H-W.
    Kollmannsberger, C. K.
    Kapoor, A.
    Hotte, S. J.
    Vanhuyse, M.
    Czaykowski, P.
    Reaume, M. N.
    Soulieres, D.
    Venner, P.
    North, S.
    Basappa, N.
    ANNALS OF ONCOLOGY, 2016, 27
  • [6] First-line sunitinib versus pazopanib in metastatic renal cell carcinoma (mRCC): Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).
    Morales, Jose Manuel Ruiz
    Wells, J. Connor
    Donskov, Frede
    Bjarnason, Georg A.
    Lee, Jae-Lyun
    Knox, Jennifer J.
    Beuselinck, Benoit
    Vaishampayan, Ulka N.
    Brugarolas, James
    Broom, Reuben James
    Bamias, Aristotelis
    Yuasa, Takeshi
    Srinivas, Sandhya
    Ernst, D. Scott
    Pezaro, Carmel Jo
    Wood, Lori
    Kollmannsberger, Christian K.
    Rini, Brian I.
    Choueiri, Toni K.
    Heng, Daniel Yick Chin
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [7] First-line sunitinib versus pazopanib in metastatic renal cell carcinoma (mRCC): Results from the international metastatic renal cell carcinoma database consortium (IMDC).
    Morales, Jose Manuel Ruiz
    Swierkowski, Marcin
    Wells, Connor
    Fraccon, Anna Paola
    La Russa, Francesca
    Donskov, Frede
    Bjarnason, Georg A.
    Lee, Jae-Lyun
    Sim, Hao-Wen
    Beuselinck, Benoit
    Wood, Lori
    Yuasa, Takeshi
    Pezaro, Carmel Jo
    Rini, Brian I.
    Szczylik, Cezary
    Choueiri, Toni K.
    Heng, Daniel Yick Chin
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [8] Burden of cancer in metastatic renal cell carcinoma (mRCC).
    Battle, Dena
    Griffith, Meghan
    Msaouel, Pavlos
    Psutka, Sarah P.
    Vaishampayan, Ulka N.
    Zhang, Tian
    Staehler, Michael D.
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL)
  • [9] SUNITINIB (SU) RECHALLENGE IN METASTATIC RENAL CELL CARCINOMA (MRCC): A SINGLE INSTITUTION EXPERIENCE
    Febbraro, Antonio
    Giordano, Guido
    ANTICANCER RESEARCH, 2014, 34 (05) : 2626 - 2627
  • [10] Cabozantinib in metastatic renal cell carcinoma (mRCC): Real world experience from the UK
    de Liano, Alfonso Gomez
    Venugopal, Balaji
    Fife, Kate
    Khasti, Luma
    Symeonides, Stefan N.
    Pettinger, Claire
    Powles, Thomas
    Rudman, Sarah Maria
    Vasudev, Naveen
    Boleti, Ekaterini
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345